Cardiovascular disease in Noonan syndrome

Archives of Disease in Childhood

Volumn 99, Issue 7, 2014, Pages 629-634

  Prendiville, Terence W ^a   Gauvreau, Kimberlee ^a,b   Tworog Dube, Erica ^c   Patkin, Lynne ^a   Kucherlapati, Raju S ^b,c   Roberts, Amy E ^a,b   Lacro, Ronald V ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LABORATORY FOR MOLECULAR MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; SOS PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ARTICLE; CARDIOVASCULAR DISEASE; CHILD; COHORT ANALYSIS; DESCRIPTIVE RESEARCH; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HEART ATRIUM SEPTUM DEFECT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; NOONAN SYNDROME; PRIORITY JOURNAL; PULMONARY VALVE STENOSIS; PULMONARY VALVULOPLASTY; RETROSPECTIVE STUDY; SECUNDUM ATRIAL SEPTAL DEFECT; SIGNAL TRANSDUCTION; TRANSLUMINAL VALVULOPLASTY; UNITED STATES; ADOLESCENT; ADULT; ANATOMICAL CONCEPTS; CONGENITAL HEART MALFORMATION; INFANT; MORPHOLOGY;

ADOLESCENT; CARDIOVASCULAR DISEASES; CHILD; FEMALE; GENOTYPE; HUMANS; INFANT; MALE; MUTATION; NOONAN SYNDROME; PHENOTYPE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84902368669     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2013-305047     Document Type: Article

References (37)

1. Noonan JA. Hypertelorism with turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child 1968;116:373-80.
2. Roberts AE, Allanson JE, Tartaglia M, et al. Noonan syndrome. Lancet 2013;381:333-42.
3. van der Burgt I. Noonan syndrome. Orphanet J Rare Dis 2007;2:4.
4. Nora JJ, Nora AH, Sinha AK, et al. The Ullrich-Noonan syndrome (Turner phenotype). Am J Dis Child 1974;127:48-55.
5. Marino B, Digilio MC, Toscano A, et al. Congenital heart diseases in children with Noonan syndrome: an expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr 1999;135:703-6. (Pubitemid 30180418)
6. Romano AA, Allanson JE, Dahlgren J, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 2010;126:746-59.
7. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol 2010;1:2-26.
8. Ferrero GB, Baldassarre G, Delmonaco AG, et al. Clinical and molecular characterization of 40 patients with Noonan syndrome. Eur J Med Genet 2008;51:566-72.
9. Sharland M, Morgan M, Smith G, et al. Genetic counselling in Noonan syndrome. Am J Med Genet 1993;45:437-40. (Pubitemid 23029634)
10. Sznajer Y, Keren B, Baumann C, et al. The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene. Pediatrics 2007;119:e1325-31. (Pubitemid 46871252)
11. Croonen EA, van der Burgt I, Kapusta L, et al. Electrocardiography in Noonan syndrome PTPN11 gene mutation - phenotype characterization. Am J Med Genet A 2008;146:350-3. (Pubitemid 351212836)
12. Hickey EJ, Mehta R, Elmi M, et al. Survival implications: hypertrophic cardiomyopathy in Noonan syndrome. Congenit Heart Dis 2011;6:41-7.
13. McCrindle BW. Independent predictors of long-term results after balloon pulmonary valvuloplasty. Valvuloplasty and Angioplasty of Congenital Anomalies (VACA) Registry Investigators. Circulation 1994;89:1751-9.
14. Ostman-Smith I, Wettrell G, Keeton B, et al. Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly. Cardiol Young 2005;15:632-42. (Pubitemid 41748558)
15. Wilkinson JD, Lowe AM, Salbert BA, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J 2012;164:442-8.
16. Burch M, Sharland M, Shinebourne E, et al. Cardiologic abnormalities in Noonan syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol 1993;22:1189-92. (Pubitemid 23285775)
17. Sharland M, Burch M, McKenna WM, et al. A clinical study of Noonan syndrome. Arch Dis Child 1992;67:178-83.
18. Shachter N, Perloff JK, Mulder DG. Aortic dissection in Noonan's syndrome (46 XY turner). Am J Cardiol 1984;54:464-5. (Pubitemid 14055791)
19. Jefferies JL, Belmont JW, Pignatelli R, et al. PTPN11 mutation associated with aortic dilation and hypertrophic cardiomyopathy in a pediatric patient with Noonan syndrome. Pediatr Cardiol 2010;31:114-16.
20. Power PD, Lewin MB, Hannibal MC, et al. Aortic root dilatation is a rare complication of Noonan syndrome. Pediatr Cardiol 2006;27:478-80. (Pubitemid 44222403)
21. Lin AE, Garver KL, Allanson J. Aortic-root dilatation in Noonan's syndrome. N Engl J Med 1987;317:1668-9. (Pubitemid 18010477)
22. Cornwall JW, Green RS, Nielsen JC, et al. Frequency of aortic dilation in Noonan Syndrome. Am J Cardiol 2013. doi: 10.1016/j.amjcard.2013.09.034 [published Online First: Epub Date]|.
23. Digilio MC, Romana Lepri F, Dentici ML, et al. Atrioventricular canal defect in patients with RASopathies. Eur J Hum Genet 2013;21:200-4.
24. Jones DA, Radford DJ, Pohlner PG. Outcome following surgical closure of secundum atrial septal defect. J Paediatr Child Health 2001;37:274-7. (Pubitemid 32619845)
25. Cheung EW, Ho SA, Tang KK, et al. Pericardial effusion after open heart surgery for congenital heart disease. Heart 2003;89:780-3. (Pubitemid 36760642)
26. Galal MO, Wobst A, Halees Z, et al. Peri-operative complications following surgical closure of atrial septal defect type II in 232 patients - a baseline study. Eur Heart J 1994;15:1381-4. (Pubitemid 24326060)
27. Rao PS. Percutaneous balloon pulmonary valvuloplasty: state of the art. Catheter Cardiovasc Interv 2007;69:747-63.
28. Rao PS, Galal O, Patnana M, et al. Results of three to 10 year follow up of balloon dilatation of the pulmonary valve. Heart 1998;80:591-5. (Pubitemid 28561695)
29. Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007;115:773-81. (Pubitemid 46294745)
30. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:873-9. (Pubitemid 37059747)
31. Tartaglia M, Kalidas K, Shaw A, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002;70:1555-63. (Pubitemid 34533902)
32. Yoshida R, Hasegawa T, Hasegawa Y, et al. Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. J Clin Endocrinol Metab 2004;89:3359-64. (Pubitemid 38951904)
33. Zenker M, Buheitel G, Rauch R, et al. Genotype-phenotype correlations in Noonan syndrome. J Pediatr 2004;144:368-74. (Pubitemid 38333896)
34. Ferreira LV, Souza SA, Montenegro LR, et al. [Phenotype variability in Noonan syndrome patients with and without PTPN11 mutation]. Arq Bras Endocrinol Metabol 2007;51:450-6.
35. Kobayashi T, Aoki Y, Niihori T, et al. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum Mutat 2010;31:284-94.
36. Pandit B, Sarkozy A, Pennacchio LA, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007;39:1007-12. (Pubitemid 47185177)
37. Razzaque MA, Nishizawa T, Komoike Y, et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 2007;39:1013-17. (Pubitemid 47185179)